<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927602</url>
  </required_header>
  <id_info>
    <org_study_id>2008-005234-79</org_study_id>
    <nct_id>NCT00927602</nct_id>
  </id_info>
  <brief_title>Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency</brief_title>
  <official_title>The Safety and Efficacy of Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism in Medical Patients With Renal Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi dell'Insubria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi dell'Insubria</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fondaparinux is a parenteral anticoagulant drug and is approved for the prevention of venous
      thromboembolism in high risk medical patients. A relevant proportion of medical patients have
      moderate to severe renal insufficiency, which is an independent risk factor for bleeding.
      This risk may be further increased when low molecular weight heparin or fondaparinux are
      administered in patients with severe renal insufficiency, defined by a creatinine clearance
      of lower than 30 mL/min. No clear indications are available to reduce such risk in patients
      who require thromboprophylaxis. A lower dose of fondaparinux, 1.5 mg daily, has been recently
      approved for the prevention of venous thromboembolism in the specific population of patients
      with a creatinine clearance between 20 and 50 mL/min (European Marketing Authorization).
      However, there are to our knowledge no clinical studies that have assessed the safety and
      efficacy of this reduced dosage in medical patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    study was stopped after enrolment of about 200 patients for slow recruitment
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>major bleeding</measure>
    <time_frame>up to 48 hours from last injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>symptomatic venous thromboembolism</measure>
    <time_frame>last treatment dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>Medical Patients</condition>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>fondaparinux</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fondaparinux</intervention_name>
    <description>once daily sc injection, 1,5 mg, max 14 days</description>
    <arm_group_label>fondaparinux</arm_group_label>
    <other_name>Arixtra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 60 years

          -  Acute medical disease requiring thromboprophylaxis according to international
             guidelines

          -  Anticipated immobilization of at least 4 days

          -  Renal insufficiency defined by creatinine clearance between 20 and 50 mL/min according
             the MDRD formula

          -  Written informed consent

        Exclusion Criteria:

          -  Active bleeding or bleeding in the previous 3 months

          -  Known bleeding diathesis

          -  Platelet count &lt; 100.000

          -  Ongoing treatment with unfractionated heparin, low molecular weight heparin,
             fondaparinux, or vitamin K antagonists

          -  Use of prophylactic doses of heparin, low molecular weight heparin, or fondaparinux in
             the previous 72 hours

          -  Life expectancy &lt; 1 month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Ageno, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Università degli Studi dell'Insubria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Dentali, MD</last_name>
    <role>Study Director</role>
    <affiliation>Università degli Studi dell'Insubria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandro Squizzato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università degli Studi dell'Insubria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Insubria</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006 Feb 11;332(7537):325-9. Epub 2006 Jan 26.</citation>
    <PMID>16439370</PMID>
  </reference>
  <reference>
    <citation>Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006 May 2;144(9):673-84.</citation>
    <PMID>16670137</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <last_update_submitted>April 23, 2012</last_update_submitted>
  <last_update_submitted_qc>April 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi dell'Insubria</investigator_affiliation>
    <investigator_full_name>Walter Ageno</investigator_full_name>
    <investigator_title>Associate Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>renal failure</keyword>
  <keyword>medical patient</keyword>
  <keyword>venous thromboembolism</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>fondaparinux</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

